Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.16 -1.10 (-2.19%)
Official Closing Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
News headline image
Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗
Via The Motley Fool
Topics Government
News headline image
Is the Fed on the Right Track? ↗
Via The Motley Fool
Topics Economy World Trade
News headline image
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Big News! U.S. and China Trade Deal Shakes Up Markets ↗
Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us. 
Via The Motley Fool
Topics World Trade
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders ↗
Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders. 
Via Benzinga
News headline image
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims' ↗
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main... 
Via Benzinga
News headline image
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
News headline image
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial ↗
Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial. 
Via Benzinga
News headline image
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary ↗
Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on Stocktwits amid heightened scrutiny on drug pricing following Trump’s vow to... 
Via Stocktwits
Topics Government
News headline image
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' ↗
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%. 
Via Benzinga
Topics Government
News headline image
Deal Dispatch: Nestlé, Coinbase, OpenAI Lead Diverse M&A Lineup As WeightWatchers Goes Bankrupt ↗
With water scarcity, AI acceleration, and GLP-1 drugs reshaping demand, deal professionals are sprinting to adapt. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started ↗
Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month. 
Via Benzinga
News headline image
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
Via Benzinga
Topics ETFs Government
News headline image
Investors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced. ↗
NOVO-NORDISK A/S-SPONS ADR could be undervalued. NYSE:NVO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
News headline image
Hims & Hers Has a Superpower in Healthcare ↗
This isn't just any growth stock. 
Via The Motley Fool
News headline image
Down Nearly 20%: Should You Buy the Dip on Eli Lilly? ↗
Via The Motley Fool
Topics Earnings Government World Trade
News headline image
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity ↗
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its... 
Via Benzinga
News headline image
Why Novo Nordisk Stock Popped After Earnings ↗
Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs. 
Via The Motley Fool
News headline image
Novo Nordisk Predicts Strong Second Half ↗
Via The Motley Fool
News headline image
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated ↗
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
News headline image
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook ↗
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition. 
Via Benzinga
Topics Earnings
News headline image
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump. ↗
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 view. 
Via Investor's Business Daily
News headline image
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth ↗
Hims & Hers is on fire right now. 
Via The Motley Fool
News headline image
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed ↗
Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments. 
Via Benzinga
News headline image
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected ↗
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now... 
Via Benzinga
Topics Bankruptcy
News headline image
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped ↗
Good news for Hims & Hers stock spooks Lilly and Novo investors. 
Via The Motley Fool
Topics Earnings
News headline image
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant? 
Via MarketBeat
Topics Earnings
News headline image
Novo Nordisk's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.